QPPV.COM KNOWLEDGE ASSESSMENT

Professional Knowledge Assessment: Mutual Recognition Procedure (MRP)

Test your understanding of the concepts covered by Mutual Recognition Procedure (MRP): How It Works.

Question 1 of 10Pass mark: 80%

Question 1 of 10 What is the legal nature of the authorisations resulting from a successful MRP?

A single Union marketing authorisation A collection of coordinated national marketing authorisations in the participating Member States A temporary scientific opinion without legal effect A single RMS authorisation that automatically replaces all national licences

Question 2 of 10 Which statement best characterises the QPPV's role in an MRP?

The QPPV automatically owns and directs the entire MRP The QPPV has no role because MRP is exclusively regulatory The QPPV should oversee relevant pharmacovigilance consequences without being assumed to own the broader regulatory procedure The QPPV replaces the RMS for all safety-related assessment activities

Question 3 of 10 Which set of records best supports traceable MRP governance?

Only the final national licences and the commercial launch dates The existing authorisation, RMS assessment, CMS questions, MAH responses, agreed product information and resulting national authorisations Only correspondence between the MAH and the RMS Only pharmacovigilance reports submitted after authorisation

Question 4 of 10 Which regulatory source should generally take precedence when resolving a question in a live MRP?

An undated internal summary prepared for training purposes A commercial launch plan The current applicable legislation and legally operative procedure-specific or national documents An old secondary article that describes a previous procedural practice

Question 5 of 10 How should Article 29(4) be understood in relation to routine MRP activities?

It is the standard final step in every MRP It is a distinct subsequent procedure that may apply when legally relevant disagreement remains unresolved It is the document that replaces the RMS assessment report It is the national implementation stage for all CMS authorisations

Question 6 of 10 Under the article's framework, when may a Member State seek to prevent normal recognition through the formal disagreement mechanisms?

Whenever it prefers a different administrative format Whenever any minor wording difference exists in national product information When the applicable legal conditions are met, including a potential serious risk to public health Whenever the MAH has not yet launched the product commercially

Question 7 of 10 Which approach to product information is most consistent with the article?

Copy the RMS national product information into every CMS without review Treat product information as separate from the scientific assessment Ensure the proposed information is coherent with the assessment and authorisation while managing applicable EU and national requirements Allow each CMS to create entirely unrelated product information without reference to the common assessment

Question 8 of 10 An MRP results in a change to a warning concerning an important identified risk. What should the MAH do from a pharmacovigilance perspective?

Treat the change as purely commercial because it arose through an authorisation procedure Assess the change within relevant PV processes and ensure safety-information records and implementation remain consistent Wait until the next periodic safety report before recording the change Remove the warning from the central safety database to avoid country discrepancies

Question 9 of 10 Which regulatory situation is the appropriate starting point for an MRP?

A medicinal product has no national authorisation and will be assessed simultaneously in several Member States A medicinal product already has a national marketing authorisation in one Member State and recognition is sought in additional Member States A medicinal product has received a Union marketing authorisation and requires national conversion A medicinal product is being assessed for the first time by a single national competent authority

Question 10 of 10 A company describes an MRP as a process that creates one European marketing authorisation valid in all participating countries. What is the professional correction?

That description is correct if the RMS has completed the assessment MRP creates a centralised authorisation only for products with safety concerns MRP coordinates recognition of an assessment but results in separate national marketing authorisations MRP creates a Union authorisation only when more than two CMSs participate

Professional Knowledge Assessment: Mutual Recognition Procedure (MRP)

Cookie Settings